GRANULES Intraday Analysis...

GRANULES Share Price

Open 103.00 Change Price %
High 103.70 1 Day N/A N/A
Low 93.60 1 Week 0.00 0.00
Close 95.00 1 Month 0.00 0.00
Volume 4650421 1 Year 0.00 0.00
52 Week High 0.00
52 Week Low 0.00
GRANULES Important Levels
Resistance 2 0.00
Resistance 1 0.00
Pivot 0.00
Support 1 0.00
Support 2 0.00
NSE INDIA Most Active Stocks
RCOM 15.30 %
RNAVAL 15.40 %
GMRINFRA 17.35 %
JPASSOCIAT 17.45 %
PNB 74.75 %
SUZLON 8.85 %
UNITECH 4.60 %
RPOWER 33.80 %
VOLTAS 551.75 %
ASHOKLEY 148.40 %
More..
NSE INDIA Top Gainers Stocks
More..
NSE INDIA Top Losers Stocks
More..

Granules India Limited (NSE: GRANULES)

GRANULES Technical Analysis 1
As on 18th May 2018 GRANULES Share Price closed @ 95.00 and we RECOMMEND N/A for LONG-TERM with Stoploss of 0.00 & N/A for SHORT-TERM with Stoploss of 0.00 we also expect STOCK to react on Following IMPORTANT LEVELS.
GRANULES Target for May
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
Granules India Limited ( NSE INDIA Symbol : GRANULES )
Sector : Healthcare And Other Stocks in Same Sector
GRANULES Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 39.21 Sideways
MFI (14) MFI is 51.33 Sideways
CCI (20) CCI is -70.98 Sideways
WILLIAM %R (14) William %R is Below -80 Over Sold
ADX (14) ADX is Above 20 & +DI is Below -DI Down Trend
PSAR Stoploss For Long Buy 91.51
10 Day Avg Volume Traded 39.56 % More then 10 Day Average Volume
GRANULES Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.granulesindia.com
GRANULES Address
GRANULES
My Home Hub
2nd Floor
Hyderabad, 500081
India
Phone: 91 40 6676 0000
Fax: 91 40 2311 5145
GRANULES Latest News
Granules India Ltd to de-list GDR in Luxembourg Stock Exchange   Equity Bulls   - 19th Mar 15
Granules India seeks delisting of GDRs   Hindu Business Line   - 17th Mar 15
US FDA inspects Granules India facility   Business Standard   - 16th Mar 15
Granules India Ltd Fixes Record Date for Stock Split   Equity Bulls   - 10th Mar 15
Granules India, Belgian firm Ajinomoto OmniChem open APIs facility   Business Standard   - 24th Feb 15
Granules India to raise Rs 250 cr via QIP: VVS Murthy   Economic Times   - 05th Feb 15
Granules India to raise Rs. 250 cr   Hindu Business Line   - 28th Jan 15
Granules India Limited   Moneycontrol.com   - 28th Jan 15
Granules India Ltd to consider quarterly results on Jan 28, 2015   Equity Bulls   - 01st Jan 15
Granules India looks at further expansion   Business Standard   - 28th Nov 13
Interactive Technical Analysis Chart Granules India Limited ( GRANULES NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Granules India Limited
GRANULES Business Profile
Granules India is in the Pharmaceuticals sector. Granules’ predecessor company, a partnership called Umbrella Laboratories, was established in 1984, and the company is based in Hyderabad, India. The Company manufactures Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) which are distributed in over 50 countries. Granules manufactures several off-patent drugs, including Paracetamol, Ibuprofen, Metformin and Guaifenesin, on a large scale for customers in the regulated and semi-regulated markets. In 2008, Granules commenced operations at its finished dosage block at Gagillapur. The new block has enabled Granules to provide products throughout the pharmaceutical value chain to customers. The state-of-the-art facility has an annual capacity of 6 billion tablets per year and is scalable up to 12 billion tablets per year. The third piece of the business is the API division. Granules manufactures APIs for several drugs including Paracetamol, Ibuprofen, Metformin and Guaifenesin through 3 facilities. The current market capitalisation stands at Rs 333.94 crore.The company has reported a consolidated sales of Rs 266.05 crore and a Net Profit of Rs 15.11 crore for the quarter ended Sep 2013. The company management includes C Nageswara Rao - Chairman, C Krishna Prasad - Managing Director, L S Sarma - Director, A P Kurian - Director, C Parthasarathy - Director, Krishna Murthy Ella - Director, Arun Rao Akinepally - Director, Harsha Chigurupati - Executive Director, Uma Chigurupati - Executive Director, K B Sankara Rao - Additional Director. It is listed on the BSE with a BSE Code of 532482 and the NSE with an NSE Code of GRANULES. Its Registered office is at 2nd Floor, 3rd Block,,My Home Hub, Hyderabad,Andhra Pradesh - 500081.